Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers

Mirzaei, Hamid Reza; Sahebkar, Amirhossein; Mohammadi, Mohsen; Yari, Reza; Salehi, Hossein; Jafari, Mohammad Hasan; Namdar, Afshin; Khabazian, Ehsan; Jaafari, Mahmoud Reza; Mirzaei, Hamed

doi:10.2174/1381612822666160303110838

Cited by 138 publications

(110 citation statements)

References 147 publications

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…MiRNAs are known as small non‐coding RNAs which have central roles in vital physiological events such as apoptosis, angiogenesis, growth, and differentiation (Gholamin et al, ; Goradel et al, ; Hashemi Goradel et al, ; Reza Mirzaei et al, ; Salarinia et al, ). Hence, deregulation of these molecules could lead to activation/inhibition various molecular and cellular targets which could contribute to initiation and progression of cancer.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA: A novel target of curcumin in cancer therapy

Mirzaei

Masoudifar

Sahebkar

et al. 2017

Journal Cellular Physiology

Self Cite

213

180

View full text Add to dashboard Cite

Curcumin is known as a natural dietary polyphenol which is extracted from Curcuma longa L. It has been shown that curcumin has a variety of pharmacological effects such as antioxidant, anti-cancer, anti-inflammatory, and anti-microbial activities. Anti-cancer effects of curcumin are due to targeting of a wide range of cellular and molecular pathways involved in cancer pathogenesis including NF-kB, MAPK, PTEN, P53, and microRNAs (miRNA) network. Multiple lines of evidence have indicated that curcumin exerts its therapeutic effects via regulating miRNA expression (e.g., miR-1, miR-7, miR-9, miR-34a, miR-181, miR-21, and miR-19) which could lead to the regulation of underlying cellular and molecular pathways involved in cancer pathogenesis. Exosomes are one of the important classes of biological vehicles which could be released from various types of cells such as cancer cells and stem cells and could change the behavior of recipient cells. It has been shown that treatment of cancer cells with different dose of curcumin leads to the release of exosomes containing curcumin. These exosomes could induce anti-cancer properties in recipient cells and reduce tumor growth. Hence, exosomes containing curcumin could be applied as powerful tools for cancer treatment. Here, we highlighted various miRNAs which could be affected by curcumin in various types of cancer. Moreover, we highlight exosomes containing curcumin as suitable therapeutic tools in cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA: A novel target of curcumin in cancer therapy

Mirzaei

Masoudifar

Sahebkar

et al. 2017

Journal Cellular Physiology

Self Cite

213

180

View full text Add to dashboard Cite

show abstract

“…Many miRNAs may be relevant as diagnostic and prognostic biomarkers for HCC patients [25,26]. We herein provide data for clinical samples obtained from 130 HCC patients, which revealed that high miR-650 levels and low LATS2 levels are associated with unfavorable clinical features and poor outcomes.…”

Section: Discussionmentioning

confidence: 92%

miR-650 Promotes the Metastasis and Epithelial–Mesenchymal Transition of Hepatocellular Carcinoma by Directly Inhibiting LATS2 Expression

Han

Yin

Zhang³

2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Previous studies have confirmed that microRNAs are involved in the metastasis and epithelial–mesenchymal transition (EMT) of malignancies. In this study, we examined whether miR-650 promotes the migration, invasion, and EMT of hepatocellular carcinoma (HCC) cells by targeting the large tumor suppressor kinase 2 gene (LATS2). Methods: qRT-PCR was used to detect expression of miR-650 in HCC tissues and paired normal tissues. MTT and Transwell assay were used to observe the effect of miR-650 on proliferation, migration and invasion of HCC cells. Western blot assay and Immunohistochemistry were performed to demonstrate association between miR-650 expression level and epithelial-mesenchymal transition (EMT) related protein. Mechanistically, Reporter luciferase assay was performed to reveal whether large tumor suppressor kinase 2 (LATS2) was a direct target of miR-650 in HCC cells. Results: We observed that miR-650 levels were largely up-regulated in HCC tissues, and that the increased expression was closely associated with the adverse clinical features of HCC patients. Additionally, the expression of LATS2, which was identified as a direct target of miR-650, can counteract the effects of miR-650 in HCC. Furthermore, we demonstrated that high miR-650 expression levels and low LATS2 expression levels in tumors may indicate a poor prognosis for HCC patients. Conclusion: In conclusion, the miR-650/LATS2 pathway may serve as a novel prognostic biomarker and an attractive therapeutic target for HCC patients.

show abstract

“…miRNA-21 or miR-21is an oncogenic miRNA and it is overexpressed in many human cancers including HCC, particularly plasma miR-21 proved to a novel circulating biomarker for HCC (Kamel et al, 2016; Mirzaei et al, 2016). Tomimaru et al reported circulating miR-21 as a novel biomarker for HCC where HCC patients' plasma were measured for miR-21 by qRT-PCR after pre and post-surgical resection.…”

Section: Current Treatment Modalities For Hepatocellular Carcinomamentioning

confidence: 99%

Recent advances in hepatocellular carcinoma therapy

Dutta

Mahato

2017

Pharmacology & Therapeutics

233

169

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), also called malignant hepatoma, is one of the deadliest cancers due to its complexities, reoccurrence after surgical resection, metastasis and heterogeneity. Incidence and mortality of HCC are increasing in Western countries and are expected to rise as a consequence of the obesity epidemic. Multiple factors trigger the initiation and progression of HCC including chronic alcohol consumption, viral hepatitis B and C infection, metabolic disorders and age. Although Sorafenib is the only FDA approved drug for the treatment of HCC, numerous treatment modalities such as transcatheter arterial chemoembolization/transarterial chemoembolization (TACE), radiotherapy, locoregional therapy and chemotherapy have been tested in the clinics. Polymeric nanoparticles, liposomes, and micelles carrying small molecules, proteins, peptides and nucleic acids have attracted great attention for the treatment of various cancers including HCC. Herein, we discuss the pathogenesis of HCC in relation to its various recent treatment methodologies using nanodelivery of monoclonal antibodies (mAbs), small molecules, miRNAs and peptides. Synopsis of recent clinical trials of mAbs and peptide drugs has been presented with a broad overview of the pathogenesis of the disease and treatment efficacy.

show abstract

Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers

Cited by 138 publications

References 147 publications

MicroRNA: A novel target of curcumin in cancer therapy

MicroRNA: A novel target of curcumin in cancer therapy

miR-650 Promotes the Metastasis and Epithelial–Mesenchymal Transition of Hepatocellular Carcinoma by Directly Inhibiting LATS2 Expression

Recent advances in hepatocellular carcinoma therapy

Contact Info

Product

Resources

About